Poseida Therapeutics Inc (PSTX)
2.73
+0.02
(+0.74%)
USD |
NASDAQ |
Nov 22, 16:00
2.86
+0.13
(+4.76%)
After-Hours: 20:00
Poseida Therapeutics Revenue (Quarterly): 71.75M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 71.75M |
| June 30, 2024 | 25.97M |
| March 31, 2024 | 28.14M |
| December 31, 2023 | 25.00M |
| September 30, 2023 | 9.352M |
| June 30, 2023 | 20.01M |
| Date | Value |
|---|---|
| March 31, 2023 | 10.34M |
| December 31, 2022 | 10.05M |
| September 30, 2022 | 116.31M |
| June 30, 2022 | 2.70M |
| March 31, 2022 | 1.435M |
| December 31, 2021 | 31.24M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.435M
Minimum
Mar 2022
116.31M
Maximum
Sep 2022
29.36M
Average
22.50M
Median
Revenue (Quarterly) Benchmarks
| Organogenesis Holdings Inc | 115.18M |
| MaxCyte Inc | 8.164M |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 20.24M |
| Total Expenses (Quarterly) | 52.01M |
| EPS Diluted (Quarterly) | 0.21 |
| Enterprise Value | 94.14M |
| Profit Margin (Quarterly) | 28.20% |
| Earnings Yield | -22.71% |
| Normalized Earnings Yield | -22.71 |